Solid Biosciences (SLDB) Non-Current Deffered Revenue (2017 - 2021)
Solid Biosciences (SLDB) posted Non-Current Deffered Revenue of $2.3 million for Q3 2021, down 47.52% sequentially from $4.3 million in Q2 2021.
Powered by 
Analysis
Solid Biosciences (SLDB) Non-Current Deffered Revenue (2017 - 2021) Analysis & Trends
Solid Biosciences has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $2.3 million in Q3 2021.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $2.3 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $2.3 million (changed N/A YoY) and the FY2020 annual result came in at $10.4 million, changed N/A from the prior year.
- Non-Current Deffered Revenue declined to $2.3 million in Q3 2021 per SLDB's latest filing, from $4.3 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $10.4 million in Q4 2020 and troughed at $2.3 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 2.26 Mn |
| Jun 30, 2021 | 4.31 Mn |
| Mar 31, 2021 | 7.00 Mn |
| Dec 31, 2020 | 10.36 Mn |
| Dec 31, 2017 | 3.11 Mn |